1. Siegel, R.L., Miller, K.D., and Jemal, A., Cancer statistics, 2020. Ca-a Cancer Journal for Clinicians.70,7-30(2020).
2. Bakiri, L., et al., Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. Journal of Experimental Medicine.214,1387-1409(2017).
3. Nguyen, V.T., Law, M.G., and Dore, G.J., Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat.16,453-463(2009).
4. Chen, C.H., et al., Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. Journal of gastroenterology and hepatology.21,1561-1566(2006).
5. Kulik, L. and El-Serag, H.B., Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology.156,477-491(2019).
6. McGlynn, K.A., Petrick, J.L., and El-Serag, H.B., Epidemiology of Hepatocellular Carcinoma. Hepatology (Baltimore, Md.).73 Suppl 1,4-13(2021).
7. Marrero, J.A., Kudo, M., and Bronowicki, J.P., The challenge of prognosis and staging for hepatocellular carcinoma. The oncologist.15 Suppl 4,23-33(2010).
8. Colagrande, S., et al., Challenges of advanced hepatocellular carcinoma. World journal of gastroenterology.22,7645-7659(2016).
9. Zhao, L., Zhao, Y., He, Y., Li, Q., and Mao, Y., The functional pathway analysis and clinical significance of miR-20a and its related lncRNAs in breast cancer. Cellular signalling.51,152-165(2018).
10. Yan, X., et al., Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model. Cancer management and research.11,273-283(2019).
11. Cao, W. and Lee, H., Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. 11,3675(2020).
12. Zhu, S., et al., LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer cell.32,310-323.e5(2017).
13. Lan, T., et al., KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Molecular cancer.18,186(2019).
14. Chang, R.M., et al., miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research.23,2593-2604(2017).
15. Bezrookove, V., et al., Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research.24,4119-4125(2018).
16. Wang, K., et al., MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis.33,2147-2154(2012).
17. Liu, G.M., Xie, W.X., Zhang, C.Y., and Xu, J.W., Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma. Journal of cellular physiology.235,1624-1636(2020).
18. Liu, G.M., Zeng, H.D., Zhang, C.Y., and Xu, J.W., Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer cell international.19,138(2019).
19. Long, J., et al., DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics.9,7251-7267(2019).
20. Long, J., et al., Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine.42,363-374(2019).
21. Long, J., et al., A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. Journal of cellular and molecular medicine.22,5928-5938(2018).
22. Wang, X., et al., Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy. Oncology reports.41,1586-1602(2019).
23. Wang, Z., et al., Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. Journal of translational medicine.18,67(2020).
24. Chaudhary, K., Poirion, O.B., Lu, L., and Garmire, L.X., Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research.24,1248-1259(2018).
25. Hu, W., et al., Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer. Molecular cancer research : MCR.16,476-485(2018).
26. Connor, A.A., et al., Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer cell.35,267-282.e7(2019).
27. Lei, H.J., et al., Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. Journal of the American College of Surgeons.203,426-435(2006).
28. Llovet, J.M., Brú, C., and Bruix, J., Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in liver disease.19,329-338(1999).
29. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (Baltimore, Md.).28,751-755(1998).
30. Chen, H., et al., APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Theranostics.9,5246-5260(2019).
31. Yasukawa, K., et al., MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion. 111,869-880(2020).
32. Zheng, Y.L., et al., LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway. Theranostics.9,796-810(2019).
33. Ding, Y., et al., Down-regulation of Long Non-coding RNA LINC01554 in Hepatocellular Cancer and its Clinical Significance. Journal of Cancer.11,3369-3374(2020).
34. Chen, S., et al., Gene amplification derived a cancer-testis long noncoding RNA PCAT6 regulates cell proliferation and migration in hepatocellular carcinoma. 8,3017-3025(2019).
35. Yang, W., Ju, H.Y., and Tian, X.F., Circular RNA-ABCB10 suppresses hepatocellular carcinoma progression through upregulating NRP1/ABL2 via sponging miR-340-5p/miR-452-5p. European review for medical and pharmacological sciences.24,2347-2357(2020).
36. Lv, J., et al., PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma. Molecular medicine reports.16,4475-4482(2017).
37. Toufektchan, E., et al., Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance. Science advances.6,eaay3511(2020).
38. Shen, T., et al., TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy. Liver international : official journal of the International Association for the Study of the Liver.40,2834-2847(2020).
39. Ritchie, M.E., et al., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research.43,e47(2015)
40. Lao, J., Chen, Y., and Li, Z.C., A Deep Learning-Based Radiomics Model for Prediction of Survival in Glioblastoma Multiforme. 7,10353(2017).
41. Lohavanichbutr, P., et al., A 13-gene signature prognostic of HPV-negative OSCC: discovery and external validation. Clinical cancer research : an official journal of the American Association for Cancer Research.19,1197-1203(2013).
42. Huitzil-Melendez, F., et al., Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J. Clin. Oncol.28,2889-2895(2010).
43. Wei, J.H., et al., A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nature communications.6,8699(2015).
44. Wu, J., et al., Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients. J. Exp. Clin. Cancer Res.36,4(2017).